Search Results - "RASKIN, Philip"

Sodium-glucose cotransporter inhibition: therapeutic potential for the treatment of type 2 diabetes mellitus by Raskin, Philip

“…Summary Results from randomized controlled trials have demonstrated that the risk of microvascular complications can be reduced by intensive glycaemic control…”
Get full text

Efficacy and Safety of the Human Glucagon-Like Peptide-1 Analog Liraglutide in Combination With Metformin and Thiazolidinedione in Patients With Type 2 Diabetes (LEAD-4 Met+TZD) by Zinman, Bernard, Gerich, John, Buse, John B, Lewin, Andrew, Schwartz, Sherwyn, Raskin, Philip, Hale, Paula M, Zdravkovic, Milan, Blonde, Lawrence

“…OBJECTIVE: To determine the efficacy and safety of liraglutide (a glucagon-like peptide-1 receptor agonist) when added to metformin and rosiglitazone in type 2…”
Get full text

Addition of Angiotensin Receptor Blockade or Mineralocorticoid Antagonism to Maximal Angiotensin-Converting Enzyme Inhibition in Diabetic Nephropathy by MEHDI, Uzma F, ADAMS-HUET, Beverley, RASKIN, Philip, VEGA, Gloria L, TOTO, Robert D

“…Aldosterone promotes glomerular and tubular sclerosis independent of angiotensin II in animal models of diabetic nephropathy. Most human studies testing the…”
Get full text

Co-stimulation modulation with abatacept in patients with recent-onset type 1 diabetes: a randomised, double-blind, placebo-controlled trial by Orban, Tihamer, MD, Bundy, Brian, PhD, Becker, Dorothy J, Prof, DiMeglio, Linda A, MD, Gitelman, Stephen E, Prof, Goland, Robin, Prof, Gottlieb, Peter A, Prof, Greenbaum, Carla J, MD, Marks, Jennifer B, Prof, Monzavi, Roshanak, MD, Moran, Antoinette, Prof, Raskin, Philip, Prof, Rodriguez, Henry, Prof, Russell, William E, Prof, Schatz, Desmond, Prof, Wherrett, Diane, MD, Wilson, Darrell M, Prof, Krischer, Jeffrey P, Prof, Skyler, Jay S, Dr, Prof

“…Summary Background The immunopathogenesis of type 1 diabetes mellitus is associated with T-cell autoimmunity. To be fully active, immune T cells need a…”
Get full text

Antigen-based therapy with glutamic acid decarboxylase (GAD) vaccine in patients with recent-onset type 1 diabetes: a randomised double-blind trial by Wherrett, Diane K, MD, Bundy, Brian, PhD, Becker, Dorothy J, Prof, DiMeglio, Linda A, MD, Gitelman, Stephen E, Prof, Goland, Robin, Prof, Gottlieb, Peter A, Prof, Greenbaum, Carla J, MD, Herold, Kevan C, Prof, Marks, Jennifer B, Prof, Monzavi, Roshanak, MD, Moran, Antoinette, Prof, Orban, Tihamer, MD, Palmer, Jerry P, MD, Raskin, Philip, Prof, Rodriguez, Henry, Prof, Schatz, Desmond, Prof, Wilson, Darrell M, Prof, Krischer, Jeffrey P, Prof, Skyler, Jay S, Dr, Prof

“…Summary Background Glutamic acid decarboxylase (GAD) is a major target of the autoimmune response that occurs in type 1 diabetes mellitus. In animal models of…”
Get full text

Coronary Artery Disease Events and Carotid Intima-Media Thickness in Type 1 Diabetes in the DCCT/EDIC Cohort by Polak, Joseph F, Backlund, Jye-Yu C, Budoff, Matt, Raskin, Philip, Bebu, Ionut, Lachin, John M

“…Background Carotid artery intima-media thickness (IMT) is associated with the risk of subsequent cardiovascular events in the general population. This…”
Get full text

Targeting of memory T cells with alefacept in new-onset type 1 diabetes (T1DAL study): 12 month results of a randomised, double-blind, placebo-controlled phase 2 trial by Rigby, Mark R, Prof, DiMeglio, Linda A, Prof, Rendell, Marc S, MD, Felner, Eric I, Prof, Dostou, Jean M, Prof, Gitelman, Stephen E, Prof, Patel, Chetanbabu M, MD, Griffin, Kurt J, Prof, Tsalikian, Eva, Prof, Gottlieb, Peter A, Prof, Greenbaum, Carla J, MD, Sherry, Nicole A, MD, Moore, Wayne V, MD, Monzavi, Roshanak, MD, Willi, Steven M, MD, Raskin, Philip, Prof, Moran, Antoinette, Prof, Russell, William E, Prof, Pinckney, Ashley, MS, Keyes-Elstein, Lynette, DrPH, Howell, Michael, PhD, Aggarwal, Sudeepta, PhD, Lim, Noha, PhD, Phippard, Deborah, PhD, Nepom, Gerald T, MD, McNamara, James, MD, Ehlers, Mario R, MBChB

“…Summary Background Type 1 diabetes results from autoimmune targeting of the pancreatic β cells, likely mediated by effector memory T (Tem) cells. CD2, a T cell…”
Get full text

Diminished Alveolar Microvascular Reserves in Type 2 Diabetes Reflect Systemic Microangiopathy by Chance, William W, Rhee, Chanhaeng, Yilmaz, Cuneyt, Dane, D. Merrill, Pruneda, M. Lourdes, Raskin, Philip, Hsia, Connie C.W

“…OBJECTIVE:--Alveolar microvascular function is moderately impaired in type 1 diabetes, as manifested by restriction of lung volume and diffusing capacity…”
Get full text

Glycemic and metabolic sub-classification of prediabetes and risk factors for cardiovascular disease in the D2d cohort by Kashyap, Sangeeta R., Desouza, Cyrus, Aroda, Vanita R., Kim, Sun H., Neff, Lisa M., Wu, Shannon S., Raskin, Philip, Pratley, Richard

“…Prediabetes represents a spectrum of metabolic abnormalities, including insulin resistance and secretory impairment, that carries increased cardiovascular…”
Get full text

Clinical Trial of Continuous Subcutaneous Insulin Infusion Versus Multiple Daily Injections in Older Adults With Type 2 Diabetes by Herman, William H, Ilag, Liza L, Johnson, Susan L, Martin, Catherine L, Sinding, Joyce, Al Harthi, Abdulaziz, Plunkett, Cynthia D, LaPorte, Frankie B, Burke, Ray, Brown, Morton B, Halter, Jeffery B, Raskin, Philip

“…OBJECTIVE:--To compare the efficacy and safety of continuous subcutaneous insulin infusion (CSII) and multiple daily injection (MDI) in older adults with…”
Get full text

A Randomized Trial of Rosiglitazone Therapy in Patients With Inadequately Controlled Insulin-Treated Type 2 Diabetes by RASKIN, Philip, RENDELL, Marc, RIDDLE, Matthew C, DOLE, Jo F, FREED, Martin I, ROSENSTOCK, Julio

“…A Randomized Trial of Rosiglitazone Therapy in Patients With Inadequately Controlled Insulin-Treated Type 2 Diabetes Philip Raskin , MD 1 , Marc Rendell , MD 2…”
Get full text

Impact of Bromocriptine-QR Therapy on Glycemic Control and Daily Insulin Requirement in Type 2 Diabetes Mellitus Subjects Whose Dysglycemia Is Poorly Controlled on High-Dose Insulin: A Pilot Study by Roe, Erin D., Raskin, Philip, Chamarthi, Bindu

“…Background. The concurrent use of a postprandial insulin sensitizing agent, such as bromocriptine-QR, a quick release formulation of bromocriptine, a dopamine…”
Get full text

Randomized trial of an inhibitor of formation of advanced glycation end products in diabetic nephropathy by Bolton, W Kline, Cattran, Daniel C, Williams, Mark E, Adler, Sharon G, Appel, Gerald B, Cartwright, Kenneth, Foiles, Peter G, Freedman, Barry I, Raskin, Philip, Ratner, Robert E, Spinowitz, Bruce S, Whittier, Frederick C, Wuerth, Jean-Paul

“…Pimagedine inhibits the formation of advanced glycation end products and slows the progression of diabetic complications in experimental models. This study was…”
Get more information

Effect of Rosiglitazone on Overweight Subjects With Type 1 Diabetes by Strowig, Suzanne M, Raskin, Philip

“…OBJECTIVE:--To evaluate the safety and effectiveness of rosiglitazone in the treatment of overweight subjects with type 1 diabetes. RESEARCH DESIGN AND…”
Get full text

Examining correlates of treatment satisfaction for injectable insulin in type 2 diabetes: lessons learned from a clinical trial comparing biphasic and basal analogues by Brod, Meryl, Cobden, David, Lammert, Morten, Bushnell, Donald, Raskin, Philip

“…Successfully managing diabetes is a complex process that includes addressing issues of drug efficacy, safety and treatment satisfaction. Additionally, the…”
Get full text

Body Weight Changes with β-Blocker Use: Results from GEMINI by Messerli, Franz H., MD, Bell, David S.H., MB, Fonseca, Vivian, MD, Katholi, Richard E., MD, McGill, Janet B., MD, Phillips, Robert A., MD, PhD, Raskin, Philip, MD, Wright, Jackson T., MD, PhD, Bangalore, Sripal, MD, Holdbrook, Fred K., PhD, Lukas, Mary Ann, MD, Anderson, Karen M., PhD, Bakris, George L., MD

“…Abstract Purpose Patients with type 2 diabetes are commonly overweight, which can contribute to poor cardiovascular outcomes. β-blockers may promote weight…”
Get full text

Efficacy and Safety of Insulin Detemir by Raskin, Philip, MD

“…Abstract In the treatment of patients with diabetes, the tear of hypoglycemia is a major barrier to initiating, maintaining, and/or intensifying insulin…”
Get full text

Randomized study of tramadol/acetaminophen versus placebo in painful diabetic peripheral neuropathy by Freeman, Roy, Raskin, Philip, Hewitt, David J., Vorsanger, Gary J., Jordan, Donna M., Xiang, Jim, Rosenthal, Norman R.

“…ABSTRACT Objective: To examine the efficacy and safety of tramadol/acetaminophen (APAP) for the management of painful diabetic peripheral neuropathy (DPN)…”
Get full text

Comparison of Insulin Monotherapy and Combination Therapy With Insulin and Metformin or Insulin and Troglitazone in Type 2 Diabetes by STROWIG, Suzanne M, LARISSA AVILES-SANTA, M, RASKIN, Philip

“…Comparison of Insulin Monotherapy and Combination Therapy With Insulin and Metformin or Insulin and Troglitazone in Type 2 Diabetes Suzanne M. Strowig , MSN,…”
Get full text

The role of lipoprotein-associated phospholipase A2 in the metabolic syndrome and diabetes by Noto, Hiroshi, Chitkara, Pranav, Raskin, Philip

“…Lipoprotein-associated phospholipase A2 (Lp-PLA2) is a novel inflammation marker. We investigated its association with other coronary risk factors and…”
Get full text